MBRXMoleculin Biotech, Inc.
0.5930USD+3.67%Mkt Cap: 11.55M $P/E: 0.043d ago
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycli…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap11.55M $
Enterprise Value4.39M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.56M $
Revenue/Share—
Last Price0.5930 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS60855D2009
Valuation
P/E (Trailing)0.04
P/E (Forward)-0.01
PEG—
EV/EBITDA-0.15
EV/Revenue—
P/S—
P/B0.21
EPS (TTM)14.91
EPS (Forward)-110.50
52W Range
0.16143% of range17.23
52W High17.23 USD
52W Low0.1614 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-223.64%
ROA-151.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.73M $
CapEx (TTM)—
FCF Margin—
FCF Yield-134.98%
Net Debt-7.12M $
Net Debt/EBITDA0.25
Balance Sheet
Debt/Equity0.02
Current Ratio0.94
Quick Ratio0.78
Book Value/Sh2.845 USD
Cash/Share0.3730 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 1, 2021
Splits
Last Split1:25
Split DateDec 1, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.33 USD
Upside (mean)+2991.6%
Target Range2.000 USD – 31.00 USD
$2.000+2991.6% to mean$31.00
# Analysts3
Ownership
Shares Out.19.48M
Float10.56M
Insiders6.41%
Institutions1.38%
Short Interest
Short Ratio1.3d
Short % Float22.36%
Short % Out.22.21%
Shares Short1.58M
Short (prev mo.)1.41M
Technical
SMA 501.865 (-68.2%)
SMA 2003.646 (-83.7%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)1.58M
Avg Vol (10d)1.10M
Technical Indicators
RSI (14)28.3
MACD-0.4132
MACD Signal-0.4652
MACD Hist.+0.0520
BB Upper2.260 USD
BB Middle0.8866 USD
BB Lower-0.4870 USD
BB Width309.86%
ATR (14)0.1528 USD
Vol Ratio (20d)0.12x